LLY.BA is trading 2.3% up today at $31,600.00 following a string of bullish corporate developments, including a major R&D collaboration and strategic acquisitions.
- Eli Lilly entered an up-to-$1.9 billion R&D and licensing collaboration with Abbisko Therapeutics to expand its pipeline through multiple novel targets.
- The company completed its acquisition of Centessa Pharmaceuticals and announced new AI-focused investment plans to reinforce growth expectations.
- These developments support continued strength for the stock following several recent positive trading sessions.